The 35 references in paper A. Novik V., A. Semenova I., A. Zhabina S., E. Imyanitov N., S. Protsenko A., Z. Akhaeva Yu., А. Жабина С., А. Новик В., А. Семенова И., Е. Имянитов Н., З. Ахаева Ю., С. Проценко А. (2015) “Treatment of advanced ovarian cancer remains a complex problem, which generates interest in researchers. Since there have been no changes in standard cytostatic treatment for last 20 years, addition of targeted drugs to the first-line therapy is considere // MODERN OPTIONS IN PERSONALIZED THERAPY OF METASTATIC CUTANEOUS MELANOMA” / spz:neicon:modonc:y:2014:i:3:p:57-64

1
Демидов Л.В., Орлова К.В. Индивидуализация лекарственного лечения меланомы кожи. Практ. онкология. 2013; 14 (4): 239–46.
(check this in PDF content)
2
Злокачественные новообразования в России в 2010 г. (заболеваемость и смертность). Под ред. В.И.Чиссова, В.В.Старинского, Г.В.Петровой. М.: Изд-во ФГБУ МНИОИ им. П.А.Герцена, 2013.
(check this in PDF content)
3
American Cancer Society. Cancer facts and figures 2013.
(check this in PDF content)
4
Avril MF, Aamdal S, Grob JJ et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004; 22: 1118–25.
(check this in PDF content)
5
Bedikian AY, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24: 4738–45.
(check this in PDF content)
6
Brose MS, Volpe P, Feldman M et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002; 62: 6997–7000.
(check this in PDF content)
7
Chapman PB, Hauschild A, Robert C et al. Updated overall survival (OS) results for BRIM3, a phase III randomized, open label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF V600E mutated melanoma. J Clin Oncol 2012; 30: 15. ASCO Ann Meeting. Abstr. 8502.
(check this in PDF content)
8
Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745–51.
(check this in PDF content)
9
Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl J Med 2011; 364: 2507–16.
(check this in PDF content)
10
Colombino M, Capone M, Lissia A et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012; 30 (20): 2522–9.
(check this in PDF content)
11
Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949–54.
(check this in PDF content)
12
Davis MJ, Schlessinger J. The genesis of Zelboraf: Targeting mutant B-Raf in melanoma. J Cell Biol 2012; 199: 15–9.
(check this in PDF content)
13
Fecher L, Cummings S, Keefe M, Alani R. Toward a molecular classification of melanoma. J Clin Oncol 2007; 25 (12): 1606–20.
(check this in PDF content)
14
Ferlay J, Shin HR, Bray F et al. GLOBOCAN 2008. 2.0. Cancer Incidence and Mortality Worldwide: IARC Cancer Base 2010; 10.
(check this in PDF content)
15
Fisher R, Larkin J. Treatment of brain metastases in patients with melanoma. Lancet Oncol 2012; 13: 434–5.
(check this in PDF content)
16
Flaherty K, Puzanov I, Sosman J. Phase I study of PLX 4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2009; 27: 15. Abstr. 9000.
(check this in PDF content)
17
Garbe C, Peris K, Hauschild A et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 2010; 46: 270–83.
(check this in PDF content)
18
Hauschild A et al. Presented at the 10th International Meeting of the Society for Melanoma Research 2013. Philadelphia, Pennsylvania.
(check this in PDF content)
19
Hodi F, O’Day S, McDermott D et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363 (8): 711–23.
(check this in PDF content)
20
Huncharek M, Caubet JF, McGarry R. Single-agent DTIC vs. combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001; 11: 75–81.
(check this in PDF content)
21
Jackson J. PLX4032 targets melanomas with BRAF Mutation: Clinical Trials on Melanoma and Other Cancers Show Great Results 2009.
(check this in PDF content)
22
Jakob JA, Bassett RL et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012; 118: 4014–23.
(check this in PDF content)
23
Korn EL, Liu PY, Lee SJ et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progressionfree and overall survival benchmarks for future phase II trials. J Clin Oncol 2008; 26: 527–34.
(check this in PDF content)
24
Larkin J, Vecchio MD, Ascierto PA et al. Vemurafenib in patients with BRAF V600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol 2014; http:// dx.doi.org/10.1016/S14702045(14)70051-8
(check this in PDF content)
25
McArthur GA, Chapman PB, Robert C et al. Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014; http://dx.doi.org/10.1016/S14702045 (14)70012-9
(check this in PDF content)
26
Menzies AM, Haydu LE, Visintin L et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 2012; 18: 3242–9.
(check this in PDF content)
27
Middleton MR, Grob JJ, Aaronson N. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158–66.
(check this in PDF content)
28
Ribas A et al. Oral presentation EADO 2014.
(check this in PDF content)
29
Robert C et al. ASCO 2012. Abstr. LBA 8509.
(check this in PDF content)
30
Sasse AD, Sasse EC, Clark LG et al. Chemoimmunotherapy vs. chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 2007; 1: CD005413.
(check this in PDF content)
31
Schuchter L. Presented at the 10th International Meeting of the Society for Melanoma Research 2013. Philadelphia, Pennsylvania.
(check this in PDF content)
32
Sinha R, Edmonds K, Newton-Bishop JA et al. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol 2012; 167: 987–94.
(check this in PDF content)
33
Smith F, Downey S, Klapper J et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008; 14 (17): 5610–8.
(check this in PDF content)
34
Wan PT, Garnett MJ, Roe SM et al. Mechanism of activation of the RAFERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855–67.
(check this in PDF content)
35
World Health Organization. Skin cancers 2013; http://www.who.int/ uv/faq/skincancer/en/index1.html; www.cancer.org/acs/groups/content/@epidemiologysurveilance
(check this in PDF content)